Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

7:36 AM ET 10-Q
Financial Results Arrow Electronics, Inc. ARW ▶ Call

Arrow Electronics Q3 2026 Results: Net Income $318M, Up 191.6% YoY

Arrow Electronics reported a significant increase in sales to $10.72 billion for the quarter ended October 3, 2026, compared to $7.71 billion in the prior-year period. Consolidated net income rose to $318.5 million, driven by strong performance in its Global Components and Global ECS segments, while the company maintained a robust balance sheet with total assets of $45.05 billion.

Key figure
Net income $318M · +191.6% YoY
7:36 AM ET 8-K
Financial Results Payoneer Global Inc. PAYO

Payoneer Global Financial Results

Payoneer Global Inc. reported third quarter 2026 financial results, featuring 2% revenue growth to $276.9 million and a 13% increase in total volume to $25.3 billion. The company highlighted significant momentum in its B2B segment, where volume grew 59% year-over-year, and noted that shareholders approved the pending merger with Nuvei in September 2026.

“Payoneer’s Q3 results show our upmarket strategy is working: B2B volume growth accelerated to 59% year-over-year, ARPU ex. interest expanded 20%+ year-over-year for a 9th consecutive quarter, and the percentage of our revenue from larger customers continues to grow.”

John Caplan, Chief Executive Officer

“We continue to work towards a targeted mid-2027 close of the Nuvei transaction. We received shareholder approval in September and are making progress with obtaining necessary regulatory approvals.”

John Caplan, Chief Executive Officer
7:35 AM ET 8-K
Financial Results Dyne Therapeutics, Inc. DYN

Dyne Therapeutics Financial Results

Dyne Therapeutics reported Q3 2026 financial results, highlighting a cash position of $684.1 million to support operations into late 2026. The company is preparing for a potential Q1 2027 U.S. launch of z-rostudirsen for DMD, which is currently under FDA priority review with a PDUFA date of January 21, 2027.

Term
Q3 2026

“As we work toward potential commercialization, we are investing across multiple programs with the goal of unlocking the full value of our FORCE platform. This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027.”

John Cox, president and chief executive officer of Dyne
7:35 AM ET 8-K
Financial Results Advanced Flower Capital Inc. AFCG

Advanced Flower Capital Financial Results

Advanced Flower Capital Inc. reported its third quarter 2026 financial results, highlighting a GAAP net investment income of $3.5 million and a net asset value (NAV) per share of $8.55. The company also repurchased approximately $1.0 million of its common stock during the quarter as part of its $5.0 million share repurchase program.

“AFC earned net investment income of $0.16 per share and grew NAV per share by $0.30 to $8.55. During the quarter, we repurchased approximately $1.0 million of our shares at roughly a 58% discount to NAV, adding $0.06 per share to NAV and bringing year-to-date accretion to $0.24. We will continue to allocate capital where it earns the best risk-adjusted return.”

Dan Neville, Chief Executive Officer
7:35 AM ET 10-Q
Financial Results Cabaletta Bio, Inc. CABA

Cabaletta Bio Q3 2026 Results: Net Loss of $53.1M, Loss Widens

Cabaletta Bio is a late-stage clinical biotechnology company focused on autoimmune diseases, specifically advancing its Phase 1/2 RESET clinical trials for rese-cel. As of October 30, 2026, the company reported 215,720,392 shares of common stock outstanding and continues to incur significant losses to fund its R&D and manufacturing partnerships with Lonza and Cellares.

Key figure
Net loss $53.1M
7:34 AM ET 10-Q
Financial Results Collegium Pharmaceutical, Inc COLL

Collegium Pharmaceutical Q3 2026 Results: Net Income $21.8M, Down 30.9% YoY

Collegium Pharmaceutical reported net income of $21.8 million for the third quarter of 2026, a decrease from $31.5 million in the prior year period, despite a slight increase in product revenues to $216.3 million. The company completed the acquisition of Azstarys during the nine-month period, contributing to a significant increase in total assets to $2.1 billion and a rise in operating expenses due to higher selling, general, and administrative costs.

Key figure
Net income $21.8M · -30.9% YoY
7:34 AM ET 10-Q
Financial Results Lucky Strike Entertainment Corp LUCK

Lucky Strike Entertainment Q1 2026 Results: Net Loss of $25.7M, Loss Widens

Lucky Strike Entertainment Corp reported total revenues of $302.6 million for the quarter ended September 27, 2026, a slight increase from $292.3 million in the prior year. However, the company saw its net loss widen to $25.7 million compared to $13.8 million previously, primarily driven by higher income tax expenses and increased selling, general, and administrative costs.

Key figure
Net loss $25.7M
7:34 AM ET 8-K
Financial Results Macom Technology Solutions Holdings, Inc. MTSI

Macom Technology Solutions Holdings Financial Results

MACOM reported record fiscal fourth quarter revenue of $424.8 million, up 62.7% year-over-year, and full-year revenue of $1.33 billion. The company achieved significant profitability improvements with fiscal year GAAP net income of $335.3 million compared to a net loss in the prior year. Management provided strong guidance for the first quarter of fiscal 2027, expecting continued revenue growth and margin expansion.

Term
FY2026

“We had a strong fiscal year 2026 and look forward to continued growth in fiscal 2027”

Stephen G. Daly, President and Chief Executive Officer
7:33 AM ET 8-K
Financial Results Sphere Entertainment Co. SPHR

Sphere Entertainment Financial Results

Sphere Entertainment reported Q3 2026 revenues of $274.3 million, a 4% increase year-over-year, driven by growth in the Sphere segment. The company reported an operating loss of $240.6 million, primarily due to results at MSG Networks, while adjusted operating income rose 8% to $39.2 million.

Term
Q3 2026

“With today’s results, our Sphere segment remains on track to deliver substantial growth this calendar year. Looking ahead, we continue to make progress on our long-term vision for Sphere, including a global network of venues and a growing slate of original content.”

James L. Dolan, Executive Chairman and CEO
7:33 AM ET 8-K
Financial Results Collegium Pharmaceutical, Inc COLL

Collegium Pharmaceutical Financial Results

Collegium Pharmaceutical reported record Q3 2026 net revenue of $216.3 million, driven by strong performance in its ADHD portfolio, including record JORNAY PM sales and the first full quarter of AZSTARYS revenue. The company reaffirmed its full-year 2026 financial guidance and expects to complete its $50 million accelerated share repurchase program by year-end.

Term
Q3 2026

“We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season. JORNAY PM reached record revenues, prescriptions and prescriber adoption, with quarterly net revenue growing 24% year-over-year.”

Vikram Karnani, President and Chief Executive Officer

“We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% of total revenue.”

Colleen Tupper, Chief Financial Officer
7:33 AM ET 10-Q
Financial Results Cronos Group Inc. CRON

Cronos Group Q3 2026 Results: Net Income $13.8M, Down 46.8% YoY

Cronos Group reported a significant increase in net revenue to $63.5 million for Q3 2026, up from $36.3 million in the prior year period, driven by growth in cannabis sales. The company achieved an operating income of $9.0 million for the quarter, a substantial improvement from the operating loss of $0.5 million in Q3 2025, while maintaining a strong cash and short-term investment position of approximately $741 million.

Key figure
Net income $13.8M · -46.8% YoY
7:32 AM ET 8-K
Financial Results Sonida Senior Living, Inc. SNDA

Sonida Senior Living Financial Results

Sonida Senior Living reported third-quarter 2026 results featuring a 15.6% increase in same-store SHOP Net Operating Income and a 200 basis point increase in occupancy to 88.6%. The company also highlighted significant acquisition activity, including the purchase of six communities in October for $135.5 million and the utilization of its ATM program to raise $39.2 million in net proceeds during the quarter.

Term
Q3 2026

“Our third quarter results demonstrate the strength of the operating platform we have built and the quality of our real estate portfolio, with continued occupancy growth translating into meaningful margin expansion and NOI growth.”

Brandon Ribar, President and Chief Executive Officer
7:32 AM ET 8-K
Financial Results Arrow Electronics, Inc. ARW

Arrow Electronics Financial Results

Arrow Electronics reported record third quarter 2026 results, with revenue of $10.7 billion, a 39% increase year-over-year. The company's performance was driven by strong demand in both its Global Components and Global Enterprise Computing Solutions segments, particularly in AI, cloud, and cybersecurity infrastructure.

Term
Q3 2026

“Arrow delivered record quarterly revenue and EPS in the third quarter, with strong momentum across both our Global Components and Global Enterprise Computing Solutions businesses, demonstrating the power of our diversified business model.”

Bill Austen, Arrow’s interim chief executive officer

“Global Enterprise Computing Solutions also experienced robust demand as customers continue to modernize their technology environments through investments in AI, cloud, cybersecurity and hybrid infrastructure solutions.”

Bill Austen, Arrow’s interim chief executive officer
7:32 AM ET 8-K
Financial Results Cronos Group Inc. CRON

Cronos Group Financial Results

Cronos Group reported record Q3 2026 financial results, with net revenue increasing 75% year-over-year to $63.5 million. The company achieved record performance in Canada, Israel, and Germany, while maintaining a strong balance sheet and continuing its share repurchase program.

Term
Q3 2026

“Cronos organically achieved records across net revenue, gross profit, and Adjusted EBITDA for the second consecutive quarter, while at the same time reducing shares outstanding.”

Mike Gorenstein, Chairman, President and CEO

“Our strategic focus on the development and production of market-leading borderless products continues to pay off, reflected in another record quarter of results.”

Mike Gorenstein, Chairman, President and CEO
7:32 AM ET 10-Q
Financial Results Twin Vee PowerCats, Co. VEEE

Twin Vee PowerCats Q3 2026 Results: Net Loss of $3.01M, Loss Widens

Twin Vee PowerCats reported a net loss of $3,013,052 for the quarter ended September 30, 2026, compared to a loss of $2,755,513 in the prior year period. Net sales decreased to $2,772,092 from $3,428,977, while the company underwent a significant one-for-37 reverse stock split in May 2026.

Key figure
Net loss $3.01M
7:32 AM ET 8-K
Financial Results Lucky Strike Entertainment Corp LUCK

Lucky Strike Entertainment Financial Results

Lucky Strike Entertainment reported Q1 2027 revenue of $302.6 million, a 3.5% increase year-over-year, despite a 2.6% decline in same-store revenue. The company reported a net loss of $25.7 million and announced the suspension of its quarterly dividend to prioritize debt reduction and capital allocation.

Term
Q1 2027

“Revenue grew in the first quarter, helped by our first full summer with two new water parks, and while same-store revenue was down, it improved every month and September comped positive.”

Thomas Shannon, Founder and CEO

“Capital spending in the quarter was the lowest in five years, and we expect the full year at roughly half its fiscal 2024 peak. With capital spending down, no acquisitions and lower litigation costs, we expect to direct meaningful free cash flow, plus proceeds from a few non-core asset sales, to debt reduction.”

Thomas Shannon, Founder and CEO
7:31 AM ET 8-K
Financial Results Installed Building Products, Inc. IBP

Installed Building Products Financial Results

Installed Building Products reported record Q3 2026 net revenue of $808.4 million, a 3.9% increase year-over-year, despite softness in residential construction. The company also declared a quarterly dividend of $0.39 per share and noted the completion of four acquisitions during the quarter adding $22 million in annual revenue.

“During the third quarter, our team stayed focused on delivering a high level of installation service to our customers. Despite continued softness in residential construction activity, our same branch sales performance continued to outperform underlying market trends reflecting market share gains and the strength of our customer relationships across our branch network.”

Jeff Edwards, Chairman and Chief Executive Officer

“While affordability and consumer confidence remain headwinds for single-family construction, we continue to focus on commercial growth, acquisition integration, operational efficiency initiatives, and disciplined capital allocation.”

Jeff Edwards, Chairman and Chief Executive Officer
7:31 AM ET 10-Q
Financial Results Black Spade Acquisition III Co BIII

Black Spade Acquisition III Q3 2026 Results: Net Income $180K

Black Spade Acquisition III Co reported net income of $2,115,385 for the nine months ended September 30, 2026, primarily driven by $4,573,722 in interest earned on cash held in its Trust Account. As a shell company, it maintains significant liquidity with $177,073,722 in the Trust Account to support a future business combination.

Key figure
Net income $180K
7:31 AM ET 10-Q
Financial Results Envoy Medical, Inc. COCH

Envoy Medical Q3 2026 Results: Net Loss of $3.93M, Loss Narrows

For the nine months ended September 30, 2026, Envoy Medical reported a net loss of $14.3 million, an improvement from the $17.2 million loss in the prior year period. The company strengthened its balance sheet through a February 2026 offering, increasing cash to $14.6 million and significantly reducing its stockholders' deficit.

Key figure
Net loss $3.93M
7:31 AM ET 8-K
Financial Results Cabaletta Bio, Inc. CABA

Cabaletta Bio Financial Results

Cabaletta Bio reported third quarter 2026 financial results, highlighting a cash position of $299.4 million which extends its operational runway into Q1 2028. The company announced plans for a BLA submission for rese-cel in myositis in Q1 2028 and initiated a second registrational study in systemic sclerosis. Management noted a recent increase in enrollment activity following a slower period in Q3 2026.

Term
Q3 2026

“We are encouraged by the favorable benefit-risk profile observed with rese-cel to date as we made deliberate choices, including construct design, standard and well-characterized manufacturing, and weight-based dosing, from the outset of its development to prioritize patient safety.”

Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta

“We are now seeing increased enrollment and screening activity, with multiple patients enrolled in the past few weeks in the registrational adult myositis study, after a slower period in 3Q26 that we believe was influenced by patient and physician caution following recently reported safety events from others in the field.”

Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta
7:31 AM ET 10-Q
Financial Results Advanced Flower Capital Inc. AFCG

Advanced Flower Capital Q3 2026 Results: Turns Profitable, Net Income $6.4M

Advanced Flower Capital Inc. reported incentive fees on net investment income of $0.8 million and $2.5 million for the three and nine months ended September 30, 2026, respectively. The company transitioned to a BDC structure on January 1, 2026, implementing a new advisory agreement with a 1.00% management fee on certain gross assets and a 17.5% incentive fee structure.

Key figure
Net income $6.4M
7:31 AM ET 10-Q
Financial Results Graham Corp GHM

Graham Q2 2026 Results: Net Income $4.64M, Up 50.1% YoY

Graham Corp reported net sales of $69.8 million for the quarter ended September 30, 2026, a 6% increase over the prior year period. Net income grew significantly to $4.6 million, or $0.39 per diluted share, driven by improved gross margins and a substantial increase in cash and cash equivalents to $71.4 million following a common stock issuance.

Key figure
Net income $4.64M · +50.1% YoY
7:31 AM ET 8-K
Financial Results Curtiss Wright Corp CW

Curtiss Wright Financial Results

Curtiss-Wright reported strong third quarter 2026 results with sales increasing 10% to $953 million and adjusted diluted EPS rising 16% to $3.94. Driven by robust demand in defense electronics and commercial nuclear solutions, the company raised its full-year 2026 guidance for sales, operating income, and EPS.

Term
Q3 2026

“Curtiss-Wright delivered a strong third quarter, highlighted by double-digit growth in both revenue and operating income, and mid-teens growth in adjusted diluted EPS, as we continue to execute on the strength of our product portfolio.”

Lynn M. Bamford, Chair and CEO

“Based on our strong year-to-date performance, we have raised our full-year guidance for all major financial metrics. We now anticipate sales growth of 8% to 10%, along with improved profitability across all three segments, as our Pivot to Growth Strategy continues to build momentum.”

Lynn M. Bamford, Chair and CEO
7:31 AM ET 8-K
Financial Results Genie Energy Ltd. GNE

Genie Energy Financial Results

Genie Energy reported third quarter 2026 results with net income increasing to $10.2 million ($0.39 per share) from $6.4 million in the prior year. While revenue decreased 8% to $127.2 million, Adjusted EBITDA grew 67% to $13.7 million, driven by normalized market conditions and gross margin expansion in the retail energy segment.

Term
Q3 2026

“Genie delivered solid bottom line gains in the third quarter versus the year-ago quarter. Income from operations climbed 72% year-over-year to $12.7 million and EPS increased by $0.14 to $0.39 per share.”

Michael Stein, Chief Executive Officer

“Adjusted EBITDA increased 67% to $13.7 million, putting us in a position to overcome the impacts of the challenging retail energy markets at the start of the year. We expect to reach our 2026 guidance of $32.5 to $40.0 million in Adjusted EBITDA.”

Michael Stein, Chief Executive Officer
7:31 AM ET 8-K
Financial Results International Seaways, Inc. INSW

International Seaways Financial Results

International Seaways reported record third quarter 2026 net income of $344 million, driven by exceptional tanker market conditions and a $53 million gain from a vessel sale. The company declared a combined dividend of $5.05 per share and completed the acquisition of Bruton Limited, adding four newbuilding VLCCs to its fleet.

Term
Q3 2026

“We delivered record quarterly net income, reflecting both exceptional tanker market conditions and the benefits of our long-term approach to fleet investment and capital allocation. While tanker markets were already strong earlier in the summer, rates surged to remarkable levels toward the end of the quarter. Our ability to capitalize on this extraordinary market reflects more than just favorable conditions; it is the result of years of disciplined capital allocation, fleet renewal and growth, all while strengthening our financial position and returning substantial capital to our shareholders.”

Lois K. Zabrocky, International Seaways President and CEO

“Our strong cash generation and financial position provide Seaways with considerable optionality in capital allocation. The completion of the Bruton transaction demonstrates our disciplined approach to deploying capital, using our shares as currency for growth while maintaining significant financial resources for futu”

Jeff Pribor, the Company’s CFO
7:31 AM ET 8-K
Financial Results Palvella Therapeutics, Inc. PVLA

Palvella Therapeutics Financial Results

Palvella Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance and Priority Review of its NDA for QTORIN™ rapamycin in microcystic lymphatic malformations. The company ended the quarter with $236.7 million in cash and is preparing for a potential U.S. commercial launch in the first half of 2027 following a February 28, 2027 PDUFA date.

Term
Q3 2026

“With the FDA’s acceptance of our NDA for QTORIN™ rapamycin in microcystic lymphatic malformations and granting of Priority Review, we believe we are closer than ever to bringing our first therapy to patients.”

Wes Kaupinen, Founder and Chief Executive Officer

“Our focus is clear: successfully obtain FDA approval and bring our first therapy to patients, advance multiple additional QTORIN™ programs to approval, and build the leading company addressing serious, rare skin diseases and vascular anomalies.”

Wes Kaupinen, Founder and Chief Executive Officer
7:31 AM ET 8-K
Financial Results Nextdoor Holdings, Inc. NXDR

Nextdoor Holdings Financial Results

Nextdoor Holdings reported Q3 2026 financial results with revenue of $78.8 million, up 14% year-over-year, and a significantly narrowed net loss of less than $1 million. The company achieved its third consecutive quarter of sequential Platform Weekly Active User (WAU) growth, reaching 24.5 million users.

Term
Q3 2026

“Q3 was another record quarter for Nextdoor, and the strongest proof yet that our transformation is well underway. Platform WAU grew for the third straight quarter to 24.5 million, revenue grew 14%, and our net loss narrowed to less than $1 million from $13 million a year ago. This progress comes from hundreds of improvements that compound on one another, and from a team that kept building long before the numbers confirmed it. In a world where more of the internet is becoming synthetic, what becomes scarce is real people, verified to a real place, helping one another. We’re carrying this momentum into the fourth quarter and beyond.”

Nirav Tolia, Nextdoor CEO and Co-Founder

“Q3 was a strong quarter of steady progress, with Adjusted EBITDA above our guidance range and Adjusted EBITDA margin up 7 points from a year ago. Our fourth quarter outlook puts full-year revenue growth in line with the low-teens range we provided last quarter. And with $28 million of operating cash flow so far this year, we’re able to keep investing in the business while opportunistically returning capital to shareholders through our buyback.”

Indrajit Ponnambalam, Nextdoor CFO
7:26 AM ET 10-Q
Financial Results Dyne Therapeutics, Inc. DYN

Dyne Therapeutics Q3 2026 Results: Net Loss of $194M, Loss Widens

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on muscle diseases using its proprietary FORCE platform. As of October 30, 2026, the company had 187,386,963 shares of common stock outstanding and expects to require substantial additional funding to advance its product candidates, which are not anticipated to reach commercialization until at least 2027.

Key figure
Net loss $194M
7:25 AM ET 10-Q
Financial Results C4 Therapeutics, Inc. CCCC

C4 Therapeutics Q3 2026 Results: Net Loss of $21.8M, Loss Narrows

C4 Therapeutics is a clinical-stage biopharmaceutical company focused on its TORPEDO platform and protein degrader candidates. As of October 30, 2026, the company had 131,317,488 shares of common stock outstanding and continues to incur significant losses to fund its research and development programs.

Key figure
Net loss $21.8M
7:25 AM ET 10-Q
Financial Results Conocophillips COP ▶ Call

Conocophillips Q3 2026 Results: Net Income $4B, Up 131.8% YoY

ConocoPhillips reported a significant increase in net income for the third quarter of 2026, reaching $4,001 million compared to $1,726 million in the same period of 2025. This growth was driven by higher sales and operating revenues, which rose to $19.4 billion for the quarter, while the company continued its shareholder return program through $5.4 billion in stock repurchases year-to-date.

Key figure
Net income $4B · +131.8% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.